Related Experiment Video
Updated: Jul 6, 2026

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
Published on: October 27, 2014
Pembrolizumab-Related Central Nervous System Vasculitis Presenting With Recurrent Ischemic Strokes
Fumiaki Henmi1, Yoshifumi Ogasawara2, Yoshikazu Uesaka1
1Neurology, Toranomon Hospital, Tokyo, JPN.
Immune checkpoint inhibitors (ICIs) can cause rare immune-related adverse events (irAEs), such as cerebral vasculitis leading to recurrent ischemic strokes. Promptly consider irAEs and initiate corticosteroids alongside ICI cessation for effective management.
Area of Science:
- Neurology
- Oncology
- Immunology
Background:
- Immune checkpoint inhibitors (ICIs) are associated with immune-related adverse events (irAEs).
- Cerebrovascular complications are rare but serious irAEs.
- Non-small-cell lung cancer patients receiving ICIs are at risk.
Related Concept Videos
Ischemic Stroke l: Introduction
Ischemic Stroke ll: Pathophysiology
Hemorrhagic Stroke l: Introduction
Hemorrhagic Stroke ll: Pathophysiology
Transient Ischemic Attack l: Introduction
Cerebral Edema ll: Pathophysiology

